BerGenBio

Investor Presentation • Dec 12, 2018

BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference

BerGenBio Presents Key Results from PhII Programme with Selective AXL Inhibitor Bemcentinib at DNB's 9th Annual Nordic Healthcare Conference

· Bemcentinib proof of concept clinical data as monotherapy and in combination

confirms focus on lung cancer & leukaemia

· AXL biomarker correlation supports bemcentinib's proposed MoA, potential for

Companion Diagnostic

· Significant milestones expected over next 12 months

Bergen, Norway, 12 Dec 2018 - BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company focused on developing a pipeline of first-in-class AXL

kinase inhibitors to treat multiple cancer indications, announces that the

Company will be presenting key results from its Phase II clinical programme with

selective AXL inhibitor bemcentinib at the DNB's 9th Annual Nordic Healthcare

Conference in Oslo, Norway, today at 10:15-10:40 CET.

The slides are available for download at the Company's website:

www.bergenbio.com/investors/presentations/

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: "We have made

significant progress during 2018 establishing clinical proof of concept for the

remarkable utility of bemcentinib in cancers with high unmet clinical need and

large market potential. We have shown that our once-a-day, oral selective AXL

inhibitor is well tolerated as a monotherapy and in combination with immune-,

targeted and chemotherapies. What is more, consistently we have seen that

efficacy scales with AXL biomarker expression leading to superior response rates

in AXL biomarker positive relapsed/refractory AML and MDS as a monotherapy as

well as non-small cell lung cancer where we are combining with the immunotherapy

blockbuster Keytruda. We have met all our operational milestones this year and

are looking forward to starting a randomised phase II programme towards the end

of H1 2019 based on key results obtained this year."

About BerGenBio ASA

BerGenBio ASA is a clinical-stage biopharmaceutical company focused on

developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple

cancer indications. The Company is a world leader in understanding the essential

role of AXL kinase in mediating cancer spread, immune evasion and drug

resistance in multiple aggressive solid and haematological cancers.

BerGenBio's lead product, bemcentinib, is a selective, potent and orally bio

-available small molecule AXL inhibitor in four Company sponsored Phase II

clinical trials in major cancer indications, with read-outs anticipated in the

second half of 2018.

AXL kinase is cell membrane receptor and an essential mediator of the biological

mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL

drives tumour survival, treatment resistance and spread, as well as suppressing

the body's immune response to tumours. AXL expression has been established as a

negative prognostic factor in many cancers. AXL inhibitors, therefore, have

potential value at the centre of cancer combination therapy, addressing

significant unmet medical needs and multiple high-value market opportunities.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO).

www.bergenbio.com

-Ends-

Contacts

Richard Godfrey, CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

+47 917 86 513

Media Relations in Norway

Jan Petter Stiff, Crux Advisers

stiff@crux.no

+47 995 13 891

International Media Relations

David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogerson

bergenbio@citigatedewerogerson.com

+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.